Top Injectable Manufacturer in Cape Verde – Reliable Pharmaceutical Solutions
Last Updated: September 13, 2026
TL;DR: Cabo Verde's medicines regulator is ERIS, created by Decreto-Lei n.º 03/2019 de 10 de janeiro, which extinguished ARFA — so any guidance naming ARFA is stale. ERIS publishes two reference-entity lists and India's CDSCO is on neither by name. Its only possible entry runs through WHO's maturity-level list, where WHO's scope for CDSCO reads Vaccines (producing). The full dossier route is open, and the recognition rules set WHO GMP equivalence as the benchmark.
Key Takeaways
ERIS, the Entidade Reguladora Independente da Saúde, was created by Decreto-Lei n.º 03/2019 de 10 de janeiro and extinguished ARFA, the Direção Geral de Farmácia and the Inspeção Geral da Saúde. Guidance naming ARFA as the licensing authority describes a body abolished in January 2019.
India's CDSCO appears on neither of the two reference-entity lists ERIS publishes. Its only possible entry is the 2025 annex's first category, a hyperlink to WHO's maturity-level list — where WHO's scope for CDSCO reads Vaccines (producing), with no medicines line.
The list is not closed. Article 5 of Deliberação n.º 03/2019 admits another regulatory authority meeting the requirements of article 6, and article 6 sets the GMP benchmark at norms at minimum equivalent to those published by WHO. That is an argument to put to ERIS in writing, not an entitlement.
Article 9(e) wants GMP evidence issued by an entity recognised by ERIS, and the only express fallback covers the active-ingredient maker alone. Physical import runs through the two licensed importer-distributors on the regulator's own register.
Introduction: What an Injectable Manufacturer in Cape Verde Has to Prove
Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Cabo Verde names a great many, twice over, and India is on neither list. ERIS publishes a reference-entity list dated 31 December 2020 and, beside it, the annex to Deliberação n.º 06/2025 de 14 de março, last updated in March 2025. Neither page says which one governs, and India's CDSCO appears on neither by name.
There is one indirect door and it is narrower than it looks. The 2025 annex's first category is not a list ERIS wrote but a hyperlink to WHO's own list of authorities at maturity levels 3 and 4 — and WHO's entry for India's CDSCO carries the scope Vaccines (producing), with no medicines line beside it. Whether ERIS would accept a CDSCO decision on a non-vaccine product through that category is unresolved on the documents we have, and it is a question to put to the regulator in writing rather than to assume.
What Sets a World-Class Injectable Manufacturer in Cape Verde Apart
Start with the regulator, because half the guidance in circulation names a body that no longer exists. ERIS — the Entidade Reguladora Independente da Saúde — was created by Decreto-Lei n.º 03/2019 de 10 de janeiro, published in Boletim Oficial n.º 03, I Série, 1.º Suplemento, and it extinguished ARFA, the Direção Geral de Farmácia and the Inspeção Geral da Saúde in one stroke. The older regulations survive, because article 3(4) provides that legal references to ARFA are deemed made to ERIS. ERIS's own authorisation page still answers its legal-framework question by naming a 2014 deliberation that was expressly revoked in 2019, so read the instruments rather than the guidance.
Then read article 5 of Deliberação n.º 03/2019 carefully, because it is the most useful sentence in the file. Recognition is available where an authorisation exists from an entity ERIS recognises or another regulatory authority that meets the requirements of article 6 — and article 6 asks only for an official authority that evaluates and authorises medicines, and one that guarantees by inspection that GMP norms at minimum equivalent to those published by WHO are respected. WHO GMP equivalence is ERIS's own express benchmark. A WHO-GMP holder has a textually grounded argument there; it has to be made in writing, and it is not self-executing.
Quality Systems Behind Every Sterile Injectable We Ship to Cape Verde
Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Dossiers are built in CTD structure with ACTD available — useful raw material here, though we found no provision making CTD or eCTD mandatory: article 10 asks for ERIS's own folder structure, distributed as a template from its site, and we found no e-submission portal.
The stability requirement is stated in the regulation itself and it is the detail most often got wrong. Article 8(1)(i) requires studies adequate to the climatic zone of Cabo Verde, named as Zona Climática IVA in line with WHO guidance and conducted per ICH — not IVB. ERIS also accepts, as an alternative to completed results, a declaration that studies have been initiated together with the protocol, which is a real concession on timelines. On sample quantities we found no provision anywhere in the recognition regulation, and no guideline language calling any quantity approximate; we did not open the full-dossier regulation, where any such requirement would sit.
Working out whether Cape Verde is reachable for your product? Talk to our regulatory team
Why Farbe Firma is the Trusted Injectable Manufacturer in Cape Verde for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Cabo Verde we can supply the WHO-format CPP, the GMP and manufacturing-authorisation evidence, Zone IVA stability packages and the certified Portuguese translations the labelling texts need. The hardest gate is article 9(e), which wants GMP evidence issued by an entity recognised by ERIS, and whose only express fallback covers the active-ingredient maker alone. We hold no Cabo Verdean authorisation and recommend no partner we have not verified.
Sterile injectables are structurally an import category here, and the register shows why. ERIS's list of licensed national operators, last updated 31 July 2026, names exactly one manufacturer in the country, Laboratórios INPHARMA, and we found no evidence that it manufactures sterile injectables — its own description of its production covers solid, liquid and semi-solid forms, and the only certification it names on its own site is ISO 9001. Physical import and wholesale distribution run through the two licensed importer-distributors on that same register, EMPROFAC, whose authorisation reference dates it to 1979, and SODIFAR, authorised in 2022. A foreign holder need not be seated in Cabo Verde: article 9(b) asks for proof of registration in the country where the applicant has its seat.
The scale is small and the geography does the rest. Population is published at 491,233 by the national statistics institute for 2021 and at 527,326 by the World Bank for 2025 — about 7% apart, so we give both. Our own approximate calculation of national health spend, multiplying a 2025 population by a 2023 per-capita figure, lands between about US$142 million and US$153 million a year, and it is indicative only. Our own approximate count of the July 2026 register is 41 licensed private pharmacies across nine inhabited islands — twenty on Santiago, one each on Maio and Brava. For a 2 to 8 °C product that thin end of the network is a single point of cold storage per island, and every unit crosses water twice.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Is India's regulator recognised by Cape Verde?
Not by name. India's CDSCO appears on neither of the two reference-entity lists ERIS publishes — neither the list dated 31 December 2020 nor the annex to Deliberação n.º 06/2025 updated in March 2025. The 2025 annex reaches India only indirectly, through a category defined by a hyperlink to WHO's list of authorities at maturity levels 3 and 4, and WHO's scope for CDSCO there reads Vaccines (producing), with no medicines line. Whether ERIS would accept a CDSCO decision on a non-vaccine product is unresolved on the documents we have.
So is Cape Verde closed to Indian manufacturers?
No. The full self-standing dossier route, AIM por processo completo under Deliberação n.º 06/2016 de 6 de maio, is open to any applicant whichever regulator authorised the product elsewhere — we did not obtain its procedural detail. And the recognition regulation carries its own catch-all: article 5 admits another regulatory authority that meets the requirements of article 6, and article 6 sets the GMP benchmark as norms at minimum equivalent to those published by WHO. A WHO-GMP holder has an argument to make there, in writing.
What does registration cost in Cape Verde, and how long does it take?
ERIS publishes 60,000 CVE for an especialidade farmacêutica and 25,000 CVE for a medicamento genérico, per medicine, where a medicine means name plus INN plus pharmaceutical form plus strength — and grouping strengths into one application does not reduce the number of fees. On timing, article 12 gives ERIS 90 calendar days from entry, extendable once by 60, but the clock suspends whenever the file is incomplete or ERIS queries the originating authority. It is a statutory period, not an elapsed-time forecast, and we found no published timeline for the full-dossier route.
Must the dossier be in Portuguese, and must it be in CTD format?
Portuguese is required for the application petition itself, and the summary of product characteristics, patient leaflet and labelling text must be supplied in certified Portuguese translation and additionally in editable form. Most of the technical file — the WHO-format CPP, quality-control methods and specifications, manufacturing authorisations, GMP certificates, the site flow chart — is accepted in Portuguese, English or French, so an English technical file is largely usable as it stands. We found no provision making CTD or eCTD mandatory, and no e-submission portal.
Can the African Medicines Agency or ECOWAS get a product into Cape Verde?
Not AMA, not yet. The treaty entered into force on 5 November 2021 and Cabo Verde acceded on 28 April 2023 and deposited on 13 July 2023, though it never signed — but we found no AMA-issued marketing authorisation, no published joint-assessment procedure and no submission portal, and AMA's own Director-General says it cannot yet function as a full single channel. ECOWAS is different: the West African joint assessment produces a WAHO recommendation, not an authorisation, and ERIS expressly names it on both of its recognition lists.
Technically Reviewed By: Maulik Sudani & Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote / View Products / FAQ / Blog
Comments